AVXL · Anavex Life Sciences Corp
United States · RS rating 4 · As of 2026-10-14
| Price | 1.49 USD |
|---|---|
| 1-day change | +0.7% |
| RS rating (overall / 1M / 3M / 12M) | 4 / 4 / 9 / 5 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 28 / 5 / 51 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +45.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +84.1% |
| Market cap (USD) | $306.7M |